The History and Development of HER2 Inhibitors
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...
Saved in:
Main Authors: | Xiaohui Xia (Author), Chen Gong (Author), Yinan Zhang (Author), Huihua Xiong (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
by: Junxia Liu, et al.
Published: (2023) -
Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier
by: Brandon M. Bordeau, et al.
Published: (2022) -
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023) -
Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
by: Bo-Wei Wang, et al.
Published: (2021) -
Cytotoxic Effect of the Her-2/Her-1 Inhibitor PKI-166 on Renal Cancer Cells Expressing the Connexin 32 Gene
by: Eriko Fujimoto, et al.
Published: (2005)